Boehringer Ingelheim and NPO Petrovax Pharm have successfully completed another stage of their work to localize the manufacturing of innovative thrombolytics in the Russian Federation. The first lots of localized Actilyse® (alteplase) for the treatment of acute ischemic stroke arrived to the healthcare institutions in Russia.
The localization of Actilyse® (alteplase) is an important part of the joint project implemented by Boehringer Ingelheim and NPO Petrovax Pharm to establish a full-cycle manufacturing of drugs for the treatment of cardiovascular diseases in Russia. The project also includes the localization of Metalyse® (tenecteplase), an innovative thrombolytic for the treatment of myocardial infarction. The locally packaged Metalyse® became available on the market in August 2017.
Overall, in two years (2017-2018), more than 22,000 doses of Metalyse® and more than 67,000 doses of Actilyse® will be manufactured for the needs of the Russian healthcare system.
Pavol Dobrocky, the Managing Director of Boehringer Ingelheim Russia, said, “We see that so far in Russia the needs in thrombolytic therapy are not fully met. For example, in 2016, only about 12,000 patients with stroke were treated with alteplase. However, the projected number of patients who should undergo thrombolysis (based on the annual number of 420 thousand cases of ischemic stroke in Russia) may be about 20,000 – 22,000 a year. We seek to improve its availability and, together with our partner NPO Petrovax Pharm, we are localizing in Russia the manufacturing of two drugs that represent the “gold standard” in thrombolytic therapy.”